← Eichor
Condition: Oligometastatic Prostate Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Oligometastatic Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06387056Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Pros
Phase 2 · 15 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT07717268The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
Phase 2 · 2 location(s) · University Medical Center Groningen · NCT07038304Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07686016Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06546267SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Phase 3 · 6 location(s) · Mayo Clinic · NCT06205316Lu-PSMA and Stereotactic Radiotherapy Versus Radiotherapy Alone for Prostate Cancer (LUST)
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT05893381OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for
NA · 15 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06462963Maximal Tumor Eradication for Oligometastatic Prostate Cancer
Phase 2/Phase 3 · 1 location(s) · RenJi Hospital · NCT06972511Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Phase 3 · 1 location(s) · Roswell Park Cancer Institute · NCT06563388An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Phase 3 · 147 location(s) · Novartis Pharmaceuticals · NCT05939414Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Phase 3 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT05352178HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymp
NA · 1 location(s) · Institut Cancerologie de l'Ouest · NCT06978296TERPS Trial for de Novo Oligometastic Prostate Cancer
Phase 2 · 10 location(s) · University of Maryland, Baltimore · NCT05223803Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Phase 2 · 3 location(s) · Peter MacCallum Cancer Centre, Australia · NCT05560659Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastat
NA · 1 location(s) · Medical University of Vienna · NCT02971358Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06369610OLIGOS: Impact of Treatment on Primary Tumour in Patients With Newly Diagnosed Oligometastatic Neoplasia of the Prostate
Phase N/A · 12 location(s) · Istituto Oncologico Veneto IRCCS · NCT06273345Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-
Phase 2 · 2 location(s) · University of Washington · NCT04175431The Impact of Radiotherapy on Oligometastatic Cancer
Phase N/A · 21 location(s) · Institut Investigacio Sanitaria Pere Virgili · NCT05933876START-MET HS Prostate Cancer. : SbrT & Androgen Receptor Therapy METastatic HSPC
NA · 2 location(s) · Instituto de Investigación en Oncología Radioterápica - Fund · NCT05209243Addressing Health Literacy With a Tailored Survivorship Care Plan
NA · 3 location(s) · Emory University · NCT06674863Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
Phase 2 · 1 location(s) · Catherine Spina · NCT05915442MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT05183074Neoadjuvant PSMA-RLT in Oligometastatic PCa
Phase 2 · 1 location(s) · Medical University of Vienna · NCT06259123Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
Phase 1 · 1 location(s) · University of Wisconsin, Madison · NCT07090148Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NA · 1 location(s) · Mayo Clinic · NCT06389786MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Phase 2 · 2 location(s) · Case Comprehensive Cancer Center · NCT06150417Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
NA · 3 location(s) · Peking University First Hospital · NCT07015138Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical
Phase 2 · 1 location(s) · Marco Oderda · NCT06758882
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.